ERBB2 and bile duct cancer: Furthermore, gastrointestinal cancers, such as colorectal cancer, gastric cancer, pancreatic cancer, and bile duct cancer, were related to low recommendation rates (<20%), wherein ERBB2 amplification, KRAS G12C, and microsatellite instability (MSI)‐High (MSI‐H) resulted in recommendations commonly.